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Introduction Pharmacokinetics: Defining
Dosimetry for Risk Assessment
by Rogene Henderson and Kulbir Bakshi
There is a dearth of information on the pharmacokinetics of
most pesticides. Furthermore, the need for information on toxic-
ity of pesticides in potentially sensitive populations such as
infants, children, pregnant women, and the elderly requires spe-
cial consideration. Therefore, the Office ofPesticides ofthe U.S.
Environmental Protection Agency (EPA) requested that the
Committee on Toxicology of the Board on Environmental
Studies and Toxicology (BEST) in the National Research
Council (NRC) conduct a workshop on the pharmacokinetics of
pesticides, with an emphasis on altered pharmacokinetics in sen-
sitive populations, especially infants and children. The NRC
Committee on Pesticides in the Diets of Infants and Children
requested that the workshop be conducted to provide informa-
tion for their study. The workshop, titled "Pharmacokinetics:
Defining the Dose for Risk Assessment" was held March 4 to 5,
1992, at the National Academy ofSciences in Washington, DC.
This workshop was a follow-up to a previous NRC workshop,
"Pharmacokinetics in Risk Assessment," organized by BEST in
1986. In the report issued from that workshop, participants rec-
ommended that a more detailed appraisal ofthe use ofpharmaco-
kinetics in risk assessment be conducted. Further, the workshop
participants suggested that the pharmacokinetics of nonvolatile
compounds, including most pesticides, which had not been con-
sidered in the 1986 workshop, needed special consideration.
The 1992 workshop focused on one aspect ofthe problem of
assessing risk from exposure to pesticides, defining the potential
dose ofthe pesticides and their metabolites to individuals (inter-
nal dose) and to the tissues where the chemical might cause harm
(biologically effective dose).
A major triumph of the past century has been our ability to
enhance the quality and quantity of the food supply. That
achievement has-been partly because of the development and
application ofpesticides to increase agricultural productivity.
However, the benefits ofpesticides must be considered in light of
the potential risks to the general population. Foodstuffs are eaten
by everyone, including the very young, the elderly, and other
potentially sensitive members ofthe population. Iftrace amounts
ofpesticides remain on foods, the pesticide residues may present
a health hazard.
To address this concern, basic pharmacokinetic information
on pesticides is required. Are they absorbed? Ifso, how long do
they stay in the body, and how are they metabolized? How much
ofthe pesticide or its metabolite reaches the target tissues in the
body? Do repeated low-level exposures induce any changes in the
body that make people more or less susceptible to the pesticide's
action? In the absence ofhuman data, the answers to these basic
questions must be obtained in animals. Consequently, we must
have some strategy for making inferences about human risk on
the basis ofdata obtained from animal studies. It is particularly
important to know if the pharmacokinetics of a pesticide is
altered in susceptible populations.
Four major topics were discussed in the workshop: (a) basic
issues in pharmacokinetics, (b) the use ofpharmacokinetic mod-
els to predict tissue dose based on external exposure and to
extrapolate animal data to humans, (c) the contribution ofextra-
hepatic metabolism to the formation of toxic metabolites, and
(d) pharmacokinetics in sensitive populations.
In the section ofthe workshop dealing with basic issues in the
use of pharmacokinetic data, Alan Wilson suggested a tiered
approach to pharmacokinetic studies in which metabolism and
pharmacokinetics are integrated into the standard toxicity test-
ing. The first tier ofstudies would determine whether the chemi-
cal is absorbed, is metabolized, and persists in the body. If the
results of the first tier are positive, the second tier of studies
should be done to determine the effect ofdose, ofrepeated dos-
ing, and ofthe different routes ofexposures on the pharmacoki-
netics of the chemical. The third tier would involve more
detailed characterization of metabolites and interactions of the
metabolites with tissues. Darrell Sumner described the major fac-
tors that might influence the pharmacokinetics of chemicals,
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processes as metabolic activation or detoxication, excretion,
absorption, or repair mechanisms, as well as the shortcomings of
the linearized multistage models used in risk assessment. Two
case studies were presented to illustrate the influence ofpharma-
cokinetics on the toxicity ofpesticides. Ronald Baron presented
studies on aldicarb that demonstrated the effect of rate ofexpo-
sure on toxicity. Blood acetylcholinesterase levels are reduced in
humans exposed to either repeated low doses ofaldicarb or to
single high doses, but severe illness occurs only in the latter case.
Charles Eldridge presented elegant studies indicating that the
induction of mammary tumors by atrazine in Sprague-Dawley
rats was related to disruption ofhormone-mediated functions in
Sprague-Dawley rats, which did not occur in F-344 rats nor
would be expected to occur in humans.
Daniel Krewski opened the section on modeling ofpharmaco-
kinetic data with a discussion ofphysiologically based pharmaco-
kinetic modeling to determine the relationship between measures
ofexternal exposure and dose of reactive metabolites reaching
target tissues. Issues in modeling related to aging, topical absorp-
tion, pregnancy, and mixed exposures were also discussed.
Harvey Clewell then presented a physiologically based mathe-
matical model of the dosimetry (pharmacokinetics) and the
action (pharmacodynamics) oforganophosphate esters and their
inhibition ofacetylcholinesterase. Robert Spear discussed the
problem ofdealing with variables in constructing physiologically
based pharmacokinetic models using benzene pharmacokinetics
as an example.
The completion ofthe first two sections ofthe workshop was
followed by a panel discussion with Daniel Menzel, Emil Pfitzer,
Penelope Fenner-Crisp, and James Stevens. The panelists
addressed the question, What is the appropriate design ofstudies
to obtain pharmacokinetic data needed for risk assessment? A
summary ofthat discussion is included in this report.
The third section ofthe workshop, which was on extrahepatic
metabolism ofxenobiotics, was opened by Alan Dahl, who dis-
cussed dosimetric factors that must be considered in estimating
the toxicity of chemicals in the respiratory tract. He also dis-
cussed the limitations ofthe ventilation-perfusion model for the
uptake of airborne toxicants and the advantages of the diffu-
sion-perfusion and perfusion-metabolism models. Robert
Bronaugh discussed skin metabolism, especially as it relates to
dermal absorption ofchemicals. Lawrence Lash pointed out the
importance ofconsidering renal metabolism in the activation
and detoxication ofcompounds via the mercapturic acid path-
way. The importance of the renal enzyme beta-lyase in the pro-
duction ofcytotoxic, mutagenic, and carcinogenic metabolites
was emphasized.
The final section ofthe workshop was devoted to discussion of
pharmacokinetics in sensitive populations and how altered phar-
macokinetics might affect the toxicity ofxenobiotics in those
individuals. Peter Shields reported on individuals with genetic
polymorphisms that either increased or decreased their suscepti-
bility to xenobiotics. Walter Rogan discussed pharmacokinetics in
lactating women and emphasized the persistence ofpesticides in
breast milk. The problems associated with trying to evaluate the
human teratogenicity ofcompounds with studies in animals was
reviewed by William Scott. The physiological changes that occur
during growth and development that mayaffect the disposition of
toxicants in the young was discussed by Ellen O'Flaherty.
William Jusko reviewed how the rapid developmental changes in
the neonate and infant can affect the pharmacokinetics and phar-
macodynamics ofcompounds. William Crom presented informa-
tion on the pharmacokinetics ofdrugs in children treated with
large doses ofcancer chemotherapeutic agents. Finally, Michael
Mayerson discussed the effects ofaging on metabolism and distri-
bution ofxenobiotics.
At the end ofthe workshop, a second panel discussion was
held with Daniel Krewski, John Doull, Alan Wilson, and
Donald Mattison. The panelists addressed the question ofhow
pharmacokinetics affects risk assessment in sensitive populations,
especially the veryyoung and the elderly.
The workshop could not have been organized without the
sponsorship of the Office of Pesticides Program of the U.S.
Environmental Protection Agency, the International Life Sciences
Institute, and the dedicated work of the staffofthe National
Research Council, especially Robert B. Beliles, project officer for
the workshop (until February 1992); Joyce Walz, project assistant
(untilJune 1992); and Ruth Danoff, project assistant.
The following papers are based on the presentations made at
the workshop. A summary ofthe two panel discussions is also
included later in this volume.
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